Arbutus Biopharma (ABUS) Equity Average (2016 - 2025)
Arbutus Biopharma (ABUS) has disclosed Equity Average for 14 consecutive years, with $77.0 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 24.62% to $77.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.0 million through Dec 2025, down 24.62% year-over-year, with the annual reading at $87.0 million for FY2025, 14.48% down from the prior year.
- Equity Average hit $77.0 million in Q4 2025 for Arbutus Biopharma, down from $80.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $167.6 million in Q1 2022 to a low of $77.0 million in Q4 2025.
- Historically, Equity Average has averaged $119.5 million across 5 years, with a median of $115.1 million in 2021.
- Biggest five-year swings in Equity Average: skyrocketed 55.14% in 2022 and later plummeted 31.62% in 2025.
- Year by year, Equity Average stood at $149.8 million in 2021, then fell by 5.74% to $141.2 million in 2022, then fell by 20.19% to $112.7 million in 2023, then decreased by 9.36% to $102.1 million in 2024, then fell by 24.62% to $77.0 million in 2025.
- Business Quant data shows Equity Average for ABUS at $77.0 million in Q4 2025, $80.2 million in Q3 2025, and $81.1 million in Q2 2025.